New Taxol® (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy

被引：46

作者：

El Alaoui, Abdessamad ^{[1
]}

Saha, Nabendu ^{[1
]}

Schmidt, Frederic ^{[1
]}

Monneret, Claude ^{[1
]}

Florent, Jean-Claude ^{[1
]}

机构：

[1] Inst Curie, CNRS, UMR 176, Ctr Rech, Paris 05, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2006年 / 14卷 / 14期

关键词：

Taxol; paclitaxel; prodrug; glucuronide;

D O I：

10.1106/j.bmc.2006.03.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Two new glucuronide paclitaxel prodrugs have been synthesized. Linked to the 2'-OH of the drug by a carbonate function, they include a self-immolative spacer bearing an arylnitro or arylamino group between the drug and the glucuronic acid residue. Both prodrugs were well detoxified and easily cleaved in the presence Of P-D-glucuronidase with fast removal of the spacer, releasing paclitaxel. The arylamino spacer-containing prodrug, more stable than the corresponding nitro analogue, was selected for further studies. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：5012 / 5019

页数：8

共 36 条

[1]

Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO

[2]

2-Q

[3]

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer [J].

Bagshawe, KD ;

Sharma, SK ;

Begent, RHJ .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) :1777-1789

[4]

MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF A FUSION PROTEIN SUITED FOR TUMOR SPECIFIC PRODRUG ACTIVATION [J].

BOSSLET, K ;

CZECH, J ;

LORENZ, P ;

SEDLACEK, HH ;

SCHUERMANN, M ;

SEEMANN, G .

BRITISH JOURNAL OF CANCER, 1992, 65 (02) :234-238

[5]

Bosslet K, 1998, CANCER RES, V58, P1195

[6]

First enzymatically activated Taxotere prodrugs designed for ADEPT and PMT [J].

Bouvier, E ;

Thirot, S ;

Schmidt, F ;

Monneret, C .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (05) :969-977

[7]

A new paclitaxel prodrug for use in ADEPT strategy [J].

Bouvier, E ;

Thirot, S ;

Schmidt, F ;

Monneret, C .

ORGANIC & BIOMOLECULAR CHEMISTRY, 2003, 1 (19) :3343-3352

[8]

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy [J].

Chari, RVJ .

ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (1-2) :89-104

[9]

Enantioselective total synthesis of ecteinascidin 743 [J].

Corey, EJ ;

Gin, DY ;

Kania, RS .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (38) :9202-9203

[10]

Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue [J].

Damen, EWP ;

Nevalainen, TJ ;

van den Bergh, TJM ;

de Groot, FMH ;

Scheeren, HW .

BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (01) :71-77

← 1 2 3 4 →